AI Summary Overview
What is Myasthenia Gravis?
Myasthenia gravis is an autoimmune neuromuscular disorder that interferes with communication between nerves and muscles. Normally, nerves release a chemical messenger called acetylcholine at the neuromuscular junction, where a nerve meets a muscle. Acetylcholine binds to receptors on the muscle and helps trigger contraction.
In myasthenia gravis, the immune system produces antibodies that interfere with proteins involved in this process. Most commonly, antibodies target acetylcholine receptors. Some people have antibodies against muscle-specific kinase, or MuSK, while other less common antibodies may also be involved.
As nerve-to-muscle signalling becomes less efficient, muscles may initially work normally but gradually weaken after repeated use. Rest often allows some strength to return.
What are the Types of Myasthenia Gravis?
Myasthenia gravis is mainly classified according to the muscles affected and antibody status. The types of myasthenia gravis are explained below:
Based on Muscles Affected:
-
Ocular Myasthenia Gravis Ocular myasthenia gravis is a form in which weakness remains limited to the muscles responsible for eye movement and eyelid control. It may affect one or both eyes, and the degree of weakness can fluctuate during the day or become more noticeable after prolonged visual activity. In some people, the condition remains confined to the eyes, while in others it may later progress to involve additional muscle groups and become generalised myasthenia gravis.
-
Generalised Myasthenia Gravis Generalised myasthenia gravis is a form in which weakness extends beyond the eye muscles and affects other voluntary muscles in the body. It can involve muscles used for facial movement, chewing, swallowing, speaking, maintaining posture, moving the limbs and, in more severe cases, breathing.The extent of involvement can vary considerably between individuals and may fluctuate over time, ranging from relatively mild generalised weakness to more severe disease requiring urgent medical care.
Based on Antibody Status:
-
AChR-Positive Myasthenia Gravis This is the most common antibody-associated form of myasthenia gravis. The immune system produces antibodies against acetylcholine receptors on the muscle surface, reducing the effectiveness of nerve-to-muscle signalling.
-
MuSK-Positive Myasthenia Gravis In this form, antibodies target muscle-specific kinase, or MuSK, a protein needed to organise and maintain acetylcholine receptors. It may be associated with prominent weakness involving the face, neck, speech and swallowing muscles.
-
Other Antibody-Positive Myasthenia Gravis Some people have antibodies against other proteins involved in maintaining the neuromuscular junction. These forms are less common and may require specialised antibody testing.
-
Seronegative Myasthenia Gravis Some people have the typical clinical and electrophysiological features of myasthenia gravis but do not have AChR or MuSK antibodies detected on standard tests. Diagnosis in these cases relies more heavily on the pattern of weakness and nerve-muscle testing.
How Common is Myasthenia Gravis in India?
Reliable nationwide prevalence data for myasthenia gravis in India are limited due to the lack of large-scale population registries. However, as per regional-based clinical reports, myasthenia gravis is more common in men than in Indian women.
What are the Stages of Myasthenia Gravis?
Myasthenia gravis does not have sequential stages that every person passes through. Instead, clinical severity may be classified according to the muscles affected and the extent of weakness.
These classes of myasthenia gravis, along with their clinical features, are provided in the table below:
| Class | Clinical Features |
| Class I | Weakness is limited to the eye muscles. Other muscle groups remain unaffected, although eyelid and eye-movement weakness may fluctuate during the day. |
| Class II | Mild weakness affects muscles beyond the eyes. A person may have limited involvement of the limbs, neck, speech or swallowing muscles but generally remains functionally independent. |
| Class III | Moderate generalised weakness is present. Muscle involvement is more noticeable and may interfere with activities such as walking, lifting, speaking, chewing or swallowing. |
| Class IV | Severe generalised weakness affects multiple muscle groups and may significantly limit mobility, swallowing, speech or daily activities. Respiratory muscles may also be involved. |
| Class V | Weakness is severe enough to require intubation and mechanical ventilation because of respiratory failure, except when ventilation is used routinely after surgery. |
What are the Symptoms of Myasthenia Gravis?
The main feature of myasthenia gravis is fatigable muscle weakness. An affected muscle may work relatively well at first but become weaker after repeated use, with some improvement after rest.
The early warning signs and severe symptoms of myasthenia gravis are listed in the table below:
| Early Warning Signs | Severe Symptoms |
|
|
Eye symptoms may become worse after prolonged reading or screen use. Speech can become softer or less clear after a long conversation, while chewing may become difficult towards the end of a meal.
Weakness involving the neck, shoulders, hips or legs can make it difficult to hold the head upright, lift the arms, stand from a chair or climb stairs.
Breathing muscle weakness is a serious symptom and requires urgent medical assessment.
Diseases Similar to Myasthenia Gravis
Neurological conditions like Lambert-Eaton syndrome and Guillain-Barré syndrome can resemble myasthenia gravis because they also cause muscle weakness.
A comparative overview of these three conditions is given below to provide a better understanding:
Myasthenia Gravis Vs. Lambert-Eaton Syndrome Vs. Guillain-Barré Syndrome
| Feature | Myasthenia Gravis | Lambert-Eaton Syndrome | Guillain-Barré Syndrome |
| How It Happens | Autoimmune disruption of nerve-to-muscle signalling | Autoimmune impairment of chemical release from nerve endings | Immune-mediated damage to peripheral nerves |
| Location | Neuromuscular junction | Neuromuscular junction | Peripheral nerves and nerve roots |
| Associated Symptoms | Drooping eyelids, double vision, fatigable weakness, swallowing or speech problems | Leg-predominant weakness, reduced reflexes and possible autonomic symptoms | Rapidly developing weakness, often beginning in the legs, with reduced reflexes |
| Severity | Ranges from eye symptoms to respiratory crisis | Can cause significant weakness and mobility problems | May progress rapidly and affect breathing |
| Can It Be Reversed? | Usually controllable with treatment, although often chronic | Symptoms may improve with treatment | Many people recover substantially, although recovery can take time |
What Causes Myasthenia Gravis?
Autoimmune myasthenia gravis develops when the immune system produces antibodies that interfere with proteins required for normal nerve-to-muscle signalling.
Possible causes of myasthenia gravis are mentioned below:
-
Acetylcholine Receptor Antibodies These antibodies block, damage or reduce acetylcholine receptors on the muscle surface, weakening the signal needed for muscle contraction.
-
MuSK and Other Antibodies Some people have antibodies against MuSK, a protein involved in maintaining acetylcholine receptors at the neuromuscular junction. Less commonly, other antibodies may be identified. Some people have typical myasthenia gravis despite negative standard antibody tests and are described as having seronegative myasthenia gravis.
-
Thymus Abnormalities The thymus is an immune system organ located behind the breastbone and is closely associated with some forms of autoimmune myasthenia gravis. Some people have abnormal immune activity within the thymus, while a smaller proportion develop a thymoma, which is a tumour of the thymus gland. >However, the exact reason the autoimmune response begins is not fully understood.
What are the Risk Factors for Myasthenia Gravis?
Myasthenia gravis can occur at any age, and no single lifestyle factor is known to cause it.
Risk factors associated with myasthenia gravis include:
-
Age and Sex: Younger-onset disease is more common in women, while later-onset disease is frequently seen in men.
-
Other Autoimmune Conditions: Autoimmune thyroid disorders and some other autoimmune diseases may occur alongside myasthenia gravis.
-
Thymus Abnormalities: Thymic changes and thymoma are associated with some forms of the disease.
-
Autoimmune Susceptibility: A personal or family tendency towards autoimmune disease may contribute to susceptibility, although autoimmune myasthenia gravis is generally not directly inherited.
Certain factors can worsen existing myasthenia gravis without causing it, including:
-
Infections
-
Surgery
-
Fever
-
Excessive heat
-
Lack of sleep
-
Physical or emotional stress
-
Pregnancy and the period after childbirth
-
Certain medicines
What are the Complications of Myasthenia Gravis?
Myasthenia gravis can lead to complications when muscle weakness becomes more severe or affects muscles involved in swallowing, breathing and mobility. Possible complications associated with myasthenia gravis are listed below:
-
Myasthenic Crisis A myasthenic crisis is a severe worsening of muscle weakness that affects breathing. Respiratory muscles may become too weak to maintain adequate ventilation. Some people require non-invasive ventilation, intubation or mechanical ventilation. A myasthenic crisis is a medical emergency.
-
Swallowing and Aspiration Problems Weak throat muscles can make swallowing difficult. Food, liquids or saliva may enter the airway, increasing the risk of choking and aspiration pneumonia.
-
Poor Nutrition Severe chewing or swallowing difficulties can reduce food and fluid intake and may lead to weight loss or dehydration.
-
Reduced Mobility and Falls Weakness in the neck, arms or legs may interfere with walking, climbing stairs, posture and other everyday activities, increasing the risk of falls.
When Should I See a Healthcare Provider?
Seek medical advice if you develop unexplained or fluctuating muscle weakness, particularly if it affects:
-
One or both eyelids
-
Eye movement
-
Speech
-
Chewing
-
Swallowing
-
Neck strength
-
Arms or legs
-
Walking or climbing stairs
People already diagnosed with myasthenia gravis should seek reassessment if their symptoms become noticeably worse, new muscle groups become affected or their usual treatment no longer controls symptoms adequately.
Seek emergency medical care for breathing difficulty, rapidly worsening weakness, severe swallowing difficulty or inability to clear saliva or respiratory secretions.
How is Myasthenia Gravis Diagnosed?
Diagnosis of myasthenia gravis is based on the pattern of muscle weakness together with blood tests and tests of nerve-to-muscle communication. Doctors may use the following tests and assessments to diagnose myasthenia gravis:
-
Medical History and Neurological Examination Doctors may ask when symptoms began, which muscles are affected, whether weakness worsens with activity and whether rest improves strength. Eye movements, eyelid position, facial movement, speech, swallowing, neck strength and limb strength may be examined.
-
Antibody Blood Tests Blood tests are used to detect AChR antibodies and MuSK antibodies. Additional antibody testing may sometimes be considered. A negative antibody test does not completely rule out myasthenia gravis.
-
Repetitive Nerve Stimulation A nerve is stimulated repeatedly while the muscle response is recorded. A decreasing muscle response can support a diagnosis of abnormal neuromuscular transmission.
-
Single-Fibre Electromyography Single-fibre EMG is a sensitive test that measures small variations in electrical communication between muscle fibres. An abnormal result can support the diagnosis, but it is not exclusive to myasthenia gravis.
-
Ice-Pack Test An ice pack may be placed over a drooping eyelid for a short period. Temporary improvement can support a diagnosis of ocular myasthenia gravis. This is a supportive test rather than a definitive diagnostic test.
-
Chest Imaging CT or MRI of the chest may be used to examine the thymus and identify enlargement or thymoma.
Diagnostic Overview Table
| Diagnostic Test | What It Assesses |
| Neurological examination | Pattern and fatigability of weakness |
| AChR antibody test | Acetylcholine receptor antibodies |
| MuSK antibody test | MuSK antibodies |
| Repetitive nerve stimulation | Repeated nerve-to-muscle responses |
| Single-fibre EMG | Neuromuscular transmission abnormalities |
| Chest CT/MRI | Thymus abnormalities |
How is Myasthenia Gravis Treated and Managed?
Treatment depends on whether myasthenia gravis is ocular or generalised, its severity, antibody status, thymus findings and the person's response to previous treatment.
The following treatment and management may be used for myasthenia gravis:
-
Symptom-Relieving Treatment Medicines may be used to improve communication between nerves and muscles and reduce fatigable weakness. These treatments can improve day-to-day muscle strength but do not directly suppress the autoimmune process responsible for the condition.
-
Immune-Suppressing Treatment When broader disease control is needed, treatment may be used to reduce abnormal immune activity. Some immune-suppressing treatments act gradually and may take weeks or months to provide their full benefit. Long-term treatment may require regular monitoring, as immune-suppressing therapy can increase the risk of adverse effects and infections.
-
Targeted Immune Therapy Newer targeted immune therapy treatments can act on specific parts of the immune system involved in myasthenia gravis. They may reduce harmful antibody activity or interfere with immune pathways that damage the neuromuscular junction. These therapies are generally reserved for selected people with generalised or difficult-to-control disease.
-
Intravenous Immunoglobulin Intravenous immunoglobulin can modify the immune response and produce a relatively rapid but temporary improvement. It may be used during:
- Severe worsening of symptoms
- Significant swallowing weakness
- Myasthenic crisis
- Preparation for selected procedures
-
Plasma Exchange Plasma exchange removes plasma containing circulating harmful antibodies and replaces it with an appropriate replacement fluid. It can produce relatively rapid improvement and may be used during severe exacerbations, significant swallowing or respiratory weakness, or myasthenic crisis. However, several treatment sessions may be required.
-
Thymectomy Thymectomy is a surgical procedure to remove the thymus gland. It is generally considered when a thymoma is present and may improve long-term disease control in selected people with generalised myasthenia gravis, even when no thymoma is found. Not everyone with myasthenia gravis requires thymectomy. Improvement after surgery may develop gradually rather than immediately.
-
Treatment of Myasthenic Crisis
A myasthenic crisis requires urgent hospital treatment, as weakness can interfere with breathing and airway protection. Management may include:
- Close respiratory monitoring
- Non-invasive breathing support
- Intubation and mechanical ventilation when required
- Treatment of infections or other triggers
- Rapid immune-modulating treatment
- Support for swallowing, hydration and nutrition when needed
Common Medicines Used to Treat Myasthenia Gravis
Common medicines that may be used to treat myasthenia gravis are listed below:
-
Pyridostigmine: Improves nerve-to-muscle signalling and provides symptomatic relief.
-
Prednisolone or Prednisone: Suppresses the autoimmune response.
-
Azathioprine: Used for long-term immune control.
-
Mycophenolate Mofetil: Used as an immunosuppressive treatment in selected patients.
-
Tacrolimus: May be used as a steroid-sparing treatment.
-
Ciclosporin: Suppresses immune activity in selected cases.
-
Rituximab: May be used for difficult-to-control disease, particularly in selected MuSK-positive cases.
-
Targeted Biologic Medicines: Complement- and FcRn-targeting treatments may be used for selected people with generalised disease.
Note: The medicines are not interchangeable. The appropriate treatment depends on disease severity, antibody status, previous treatment and individual health factors. Medicines should only be taken under medical supervision.
Living With Myasthenia Gravis: Daily Challenges and Caregiving
Myasthenia gravis can make everyday life unpredictable, as muscle strength may change during the day.
Some of the challenges and essential care points for myasthenia gravis patients are outlined below:
-
Challenges
- Changing Strength: Muscle weakness can worsen after repeated activity, making it more difficult to complete daily tasks.
- Mobility Difficulties: Weakness in the legs may make walking, climbing stairs or standing from a chair difficult.
- Eating and Speaking Problems: Chewing, swallowing and prolonged talking may become tiring when facial or throat muscles are affected.
- Work and Social Activities: Fluctuating symptoms can make work schedules, travel and social plans more difficult to manage.
-
Patient Well-Being
- Plan Activities Carefully: More demanding tasks may be easier when muscle strength is better, with rest periods between activities.
- Follow Treatment Regularly: Taking prescribed treatment consistently and avoiding known triggers is important to control symptoms.
- Monitor Worsening Symptoms: Increasing difficulty with swallowing, walking or breathing should be medically assessed promptly.
-
Expenses
- Consultation Costs: Regular appointments with neurologists and other specialists may contribute to ongoing healthcare expenses.
- Treatment and Medicine Costs: Long-term medicines, investigations and advanced treatments can add to recurring costs.
- Hospitalisation Costs: Severe flare-ups or myasthenic crisis may require hospital admission, intensive care or respiratory support, substantially increasing expenses.
What is the Prognosis for Myasthenia Gravis?
Myasthenia gravis is usually a chronic but treatable condition. Its course varies between individuals and is generally fluctuating rather than steadily progressive.
Some people with ocular disease remain limited to eye symptoms, while others develop generalised weakness. Periods of improvement or remission may occur, although some people require long-term treatment.
With appropriate treatment, many people can maintain good function, independence and a normal or near-normal life expectancy.
Myasthenic crisis remains the most serious short-term complication and requires urgent treatment.
How Can I Prevent Myasthenia Gravis?
There is currently no established way to prevent autoimmune myasthenia gravis from developing. However, people who already have the condition may reduce the likelihood of worsening symptoms by:
-
Taking medicines as prescribed
-
Treating infections promptly
-
Getting adequate sleep
-
Avoiding excessive physical exhaustion
-
Avoiding excessive heat if it worsens symptoms
-
Checking new medicines for potential effects on myasthenia gravis
-
Informing healthcare professionals about the condition before surgery or anaesthesia
-
Attending regular neurological follow-up
The above measures cannot prevent every flare, but may help reduce avoidable triggers and identify worsening symptoms earlier.
Myasthenia Gravis Treatment Cost in India
Myasthenia gravis treatment costs vary considerably according to disease severity and the type of care required.
The table below provides an indicative overview of myasthenia treatment costs in India:
| Treatment or Test | Approximate Cost in India |
| Neurologist consultation | ₹800 - ₹2,500 per visit |
| AChR antibody test | ₹1,200 - ₹5,000 |
| MuSK antibody test | ₹5,000 - ₹8,000 |
| Repetitive nerve stimulation | ₹1,500 - ₹5,000 |
| Single-fibre EMG | ₹3,000 - ₹8,000 |
| Chest CT | ₹2,500 - ₹7,000 |
| Pyridostigmine 60 mg | ₹10 - ₹25 per tablet |
| IVIG | ₹1 lakh onwards per treatment course |
| Plasma exchange | ₹20,000 - ₹95,000 per session |
| Thymectomy | ₹3 - ₹6.5 lakh |
Note: These costs are indicative and can vary by city, hospital, dose, treatment duration and healthcare setting. Myasthenic crisis involving intensive care and respiratory support can substantially increase the overall expense.
Does Health Insurance Cover Myasthenia Gravis in India?
Yes. Health insurance covers the treatment for myasthenia gravis, depending on the policy terms. Covered expenses may include hospitalisation for myasthenic crisis, ICU care, respiratory support, medically necessary IVIG or plasma exchange during admission and thymectomy.
Routine neurologist consultations, diagnostic testing and long-term medicines are usually outpatient expenses and may require a policy with suitable OPD benefits.
If myasthenia gravis is a pre-existing disease, a waiting period of up to 36 months may apply, depending on the policy.
How Much Health Insurance Coverage is Needed for Myasthenia Gravis Treatment?
There is no fixed sum insured specifically recommended for myasthenia gravis.
A health insurance coverage of around ₹10 to ₹20 lakh may provide protection against hospitalisation expenses. A higher coverage of ₹25 lakh or more may offer broader protection against major hospital admissions, ICU treatment, respiratory support or other significant healthcare expenses.
The overall sum insured should be selected according to broader healthcare needs rather than myasthenia gravis alone.
FAQs
-
Q1. Is myasthenia gravis contagious?
Ans: No. Myasthenia gravis cannot spread from one person to another. -
Q2. Is myasthenia gravis inherited?
Ans: Autoimmune myasthenia gravis is generally not directly inherited. Congenital myasthenic syndromes are separate genetic disorders. -
Q3. Does myasthenia gravis always begin with eye symptoms?
Ans: No. Eye symptoms in myasthenia gravis are common, but some people first develop facial, throat, neck or limb weakness.
-
References
-
https://www.ninds.nih.gov/sites/default/files/2025-05/myasthenia-gravis.pdf
-
https://pmc.ncbi.nlm.nih.gov/articles/PMC10645219/
-
https://pmc.ncbi.nlm.nih.gov/articles/PMC9491427/
-
https://irdai.gov.in/health-dept
-
https://pubmed.ncbi.nlm.nih.gov/40675734/
-
https://pmc.ncbi.nlm.nih.gov/articles/PMC10645219/
-
https://pmc.ncbi.nlm.nih.gov/articles/PMC3108086/
-
https://pmc.ncbi.nlm.nih.gov/articles/PMC10041265/
-
